Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hodgkin's Lymphoma - Relapsed/Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03770416
What this trial is testing

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Who this might be right for
Central Nervous System B-Cell Non-Hodgkin LymphomaRecurrent Central Nervous System LymphomaRefractory Central Nervous System Lymphoma
M.D. Anderson Cancer Center 18
Very early researchUnknownNCT06277011
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
Anhui Provincial Hospital 18
Testing effectiveness (Phase 2)Ended earlyNCT00479167
What this trial is testing

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Who this might be right for
Follicular Lymphoma
Rush University Medical Center 1
Early research (Phase 1)Study completedNCT00005946
What this trial is testing

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Testing effectiveness (Phase 2)Study completedNCT02332980
What this trial is testing

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue+20 more
Mayo Clinic 65
Testing effectiveness (Phase 2)Looking for participantsNCT06377540
What this trial is testing

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Who this might be right for
Autologous Stem Cell TransplantClassic Hodgkin Lymphoma
Masonic Cancer Center, University of Minnesota 28
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Early research (Phase 1)Active Not RecruitingNCT03478462
What this trial is testing

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Who this might be right for
Pediatric Solid TumorPediatric LymphomaPediatric Brain Tumor+5 more
Cellectar Biosciences, Inc. 30
Testing effectiveness (Phase 2)Study completedNCT03209973
What this trial is testing

Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
BeiGene 70
Early research (Phase 1)Active Not RecruitingNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Testing effectiveness (Phase 2)Study completedNCT01030900
What this trial is testing

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Who this might be right for
Hodgkin LymphomaDiffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT00047021
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
Case Comprehensive Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT00636311
What this trial is testing

A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma

Who this might be right for
Hodgkin Disease
Istituto Clinico Humanitas 13
Early research (Phase 1)WithdrawnNCT02640833
What this trial is testing

Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNon-Hodgkin Lymphoma
AbbVie
Early research (Phase 1)Study completedNCT05564806
What this trial is testing

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Advanced Solid TumorsRelapsed Or Refractory Non-Hodgkin Lymphoma
Eucure (Beijing) Biopharma Co., Ltd 9
Testing effectiveness (Phase 2)Ended earlyNCT00072449
What this trial is testing

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

Who this might be right for
Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Testing effectiveness (Phase 2)Study completedNCT00792467
What this trial is testing

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

Who this might be right for
Hodgkin's Lymphoma
Italfarmaco 24
Testing effectiveness (Phase 2)WithdrawnNCT01170052
What this trial is testing

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Mantle Cell Lymphoma
Charite University, Berlin, Germany 20
Early research (Phase 1)Study completedNCT02594384
What this trial is testing

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
OrphAI Therapeutics 62
Very early researchUnknownNCT04626739
What this trial is testing

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Who this might be right for
Refractory Indolent Adult Non-Hodgkin Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 100
Next Page